BIOTECH

BIOTECH

Hope for Dry AMD: Novel Gene Therapy Completes First Human Safety Trial

Paris, France – April 23, 2026 – In a significant development for the millions suffering...

Read more

BIOTECH

Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

Paris, France, January 22, 2026 – PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing...

Read more

BIOTECH

ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate

Next-generation therapeutic vaccines company also welcomes industry veteran Eric Halioua to board, as executive chairman....

Read more

BIOTECH

KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer

Phase 2 data demonstrated 17.5-month median overall survival in advanced, chemo-refractory patients with microsatellite stable...

Read more

BIOTECH

Lattice Medical raises €43 million to transform post-cancer reconstruction

Lille, France, October 23, 2025 – LATTICE MEDICAL, a French Medtech company specializing in tissue...

Read more